[Nanoparticles for brain delivery of drugs or contrast agents. Application to Alzheimer's disease].
The treatment and the diagnosis of brain diseases like Alzheimer's are nowadays a real challenge. In fact the brain delivery of drugs or contrast agents is very difficult due to the low permeability of the blood brain barrier (BBB) which is situated in brain capillaries and assures a high protection of the brain against exogenous molecules or particles. Among the different strategies that have been proposed to increase the passage of drugs through the barrier, a non-invasive one is based on the use of colloidal carriers called nanoparticles. These nanometric objects chosen for their biocompatibility and biodegradation exhibit several fates and distributions according to their composition and structures, defining the three generations of nanoparticles described up to now. The application of nanoparticles to the treatment and diagnosis of Alzheimer's disease is actually investigated in a European project. Recent studies reveal that more than 3 million people in Europe are afflicted with Alzheimer's disease. New treatments are urgently needed, as are diagnostic tests that can detect the disease earlier. The strategies developed in this project are based on the design of new carriers able to pass through the BBB and to interact with β-amyloid peptide in order to (1) detect already formed brain plaques, aiming to diagnose the disease and (2) avoid peptide aggregation which is toxic for neurons, for the purpose of discovering a new therapeutic approach for Alzheimer's disease.